المؤلفون: Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Clinical Oncology, Faculty of Medicine, Menoufia University. Shebin Al-Kom, Egypt., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Subbiah V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Tsimberidou AM; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: JCO precision oncology [JCO Precis Oncol] 2022 Jul; Vol. 6, pp. e2100512.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Circulating Tumor DNA*/genetics , Neoplasms*/genetics, Biomarkers, Tumor/genetics ; Humans ; Liquid Biopsy ; Treatment Outcome

المؤلفون: Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Polivka J; Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Department of Neurology, University Hospital Pilsen, Pilsen, Czech Republic., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Treskova I; Department of Plastic Surgery, University Hospital Pilsen, Pilsen, Czech Republic., Pivovarcikova K; Department of Pathology, University Hospital Pilsen, Pilsen, Czech Republic., Fikrle T; Department of Dermatovenerology, University Hospital Pilsen, Pilsen, Czech Republic., Woznica V; Department of Plastic Surgery, University Hospital Pilsen, Pilsen, Czech Republic., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA., Pesta M; Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic; Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: fjanku@me.com.

المصدر: ESMO open [ESMO Open] 2022 Feb; Vol. 7 (1), pp. 100357. Date of Electronic Publication: 2021 Dec 20.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 101690685 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2059-7029 (Electronic) Linking ISSN: 20597029 NLM ISO Abbreviation: ESMO Open Subsets: MEDLINE

مواضيع طبية MeSH: Circulating Tumor DNA*/genetics , Melanoma*/genetics , Mutation* , Proto-Oncogene Proteins B-raf*/genetics, Humans ; Polymerase Chain Reaction

المؤلفون: Lapin M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Hematology and Oncology, Stavanger University Hospital, Stavanger, Norway., Huang HJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Chagani S; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Javle M; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Shroff RT; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Division of Hematology/Oncology, University of Arizona Cancer Center, Tucson, AZ., Pant S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Gouda MA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Raina A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Madwani K; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Holley VR; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Call SG; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Dustin DJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Lanman RB; Guardant Health, Redwood City, CA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX., Raymond VM; Guardant Health, Redwood City, CA., Kwong LN; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: JCO precision oncology [JCO Precis Oncol] 2022 Feb; Vol. 6, pp. e2100197.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 101705370 Publication Model: Print Cited Medium: Internet ISSN: 2473-4284 (Electronic) Linking ISSN: 24734284 NLM ISO Abbreviation: JCO Precis Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Bile Duct Neoplasms*/blood , Bile Duct Neoplasms*/drug therapy , Bile Duct Neoplasms*/enzymology , Bile Duct Neoplasms*/genetics , Cholangiocarcinoma*/blood , Cholangiocarcinoma*/drug therapy , Cholangiocarcinoma*/enzymology , Cholangiocarcinoma*/genetics , Circulating Tumor DNA*/blood , Circulating Tumor DNA*/genetics , Enzyme Inhibitors*/pharmacology , Isocitrate Dehydrogenase*/antagonists & inhibitors, Bile Ducts, Intrahepatic ; Clonal Evolution ; Humans ; Prognosis